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Abstract
Background: A relatively high incidence of pathological conditions in retrieved femoral heads,
including a group of patients having low grade B-cell lymphoma, has been described before. At short
term follow up none of these patients with low-grade B-cell lymphoma showed evidence of
systemic disease. However, the long term follow up of these patients is not known.
Methods: From November 1994 up to and including December 2005 we screened all femoral
heads removed at the time of primary total hip replacement histopathologically and included them
in the bone banking protocol according to the guidelines of the American Associations of Tissue
Banks (AATB) and the European Association of Musculo-Skeletal Transplantation (EAMST). We
determined the percentage of B-cell lymphoma in all femoral heads and in the group that fulfilled
all criteria of the bone banking protocol and report on the long-term follow-up.
Results: Of 852 femoral heads fourteen (1.6%) were highly suspicious for low-grade B-cell
lymphoma. Of these 852 femoral heads, 504 were eligible for bone transplantation according to the
guidelines of the AATB and the EAMST. Six femoral heads of this group of 504 were highly
suspicious for low-grade B-cell lymphoma (1.2%). At long term follow up two (0.2%) of all patients
developed systemic malignant disease and one of them needed medical treatment for her condition.
Conclusion: In routine histopathological screening we found variable numbers of low-grade B-cell
lymphoma throughout the years, even in a group of femoral heads that were eligible for bone
transplantation. Allogenic transmission of malignancy has not yet been reported on, but surviving
viruses are proven to be transmissible. Therefore, we recommend the routine histopathological
evaluation of all femoral heads removed at primary total hip arthroplasty as a tool for quality
control, whether the femoral head is used for bone banking or not.
Background
Allograft donor bone is successfully used in reconstructive
tumor surgery and revision of total hip arthroplasties
[1,2]. Bone banks collect femoral heads according to the
safety procedures of the American Associations of Tissue
Banks (AATB) and the European Association of Musculo-
Skeletal Transplantation (EAMST) [3,4]. These constantly
updated guidelines are of the utmost importance in order
to prevent the transmission of infectious diseases.
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reports of living cells within donor tissue after routine cry-
opreservation [5-7]. The potential risk of transmission of
diseases from donor to recipient by these surviving cells
remains uncertain, but there have been several reports on
the development of infectious diseases due to the trans-
plantation of contaminated allograft bone [8-14]. Previ-
ously we, and another group, recommended routine
histological examination in the screening protocol
because of a relatively high percentage of pathological
conditions in retrieved femoral heads, including a group
of patients having low grade B-cell lymphoma [15,16]. At
short term follow up none of the patients with low-grade
B-cell lymphoma in the femoral head showed evidence of
systemic disease. However, the clinical consequences of
these findings remained unknown. Therefore we contin-
ued our prospective study to screen histopathologically all
retrieved femoral heads after total hip arthroplasty,
including those that were not suitable for bone banking.
We determined the percentage of B-cell lymphoma in all
femoral heads, and in the group that met all criteria of the
bone banking protocol, and will now report on the long-
term follow-up.
Methods
From November 1994 through December 2005 all femo-
ral heads removed at the time of primary total hip replace-
ment were collected according to the guidelines of the
AATB and EAMST [3,4]. All patients gave written and
signed informed consent. They were screened by a ques-
tionnaire covering their medical, social and sexual history.
The questionnaire was based on pre-existing forms, fol-
lowed the guidelines of the AATB and EAMST, and was
written in the patient's native language. Additionally, the
patients were interviewed by a doctor. A thorough physi-
cal and routine blood examination was performed. Blood
was collected to determine the blood group, Rhesus fac-
tor, and white blood cell count. Screening tests were per-
formed to exclude syphilis, HBV and hepatitis C virus
(HCV), cytomegalovirus (CMV), HIV1 and 2 and HTLV
type 1. An increased ESR was also used as a criterion for
exclusion. All donors were retested for HIV1 and 2, syph-
ilis, HBV, HCV and HTLV1 six months after the donation,
taking into account the negative window period. After
resection of the femoral heads, swabs from bone and cap-
sule were taken for aerobic and anaerobic cultures. A core
bone biopsy specimen (1 cm3) and a part of the capsule
were retrieved for histopathological examination. Cores
or biopsies were, in general, too big for electrolytical
decalcification, as is routine in the laboratory for trephine
biopsies. Thus they were decalcified in Kirstensen' solu-
tion in a daily controlled fashion. After decalcification,
biopsies were routinely processed and microscopy was
performed on Hematoxylin and Eosin. When required for
more precise examination (i.e. lymphocytic collections
that were monotoneous) additional stains and immuno-
histochemistry were performed to confirm diagnosis and,
if possible, classified.
Grafts were stored at -80°C and six months later another
blood examination followed. Earlier we described our
bone bank screening procedure in detail [15]. Femoral
heads of patients which were excluded somewhere in this
bone banking selection process were sent for routine his-
topathological examination only.
Non-Hodgkin Lymphoma was diagnosed according to
routine diagnostic procedures in the laboratory by expert
hematopathologists. Criteria for diagnosis were an
increase in lymphoid cells in general characterized by an
interstitial pattern of infiltration, or paratrabecular locali-
zation of two or more nodules to packed marrow of cells
with short chain restriction (kappa or Lambda) and uni-
form B-cell marker (CD20, CD79a, CD23 expression). In
cases of concomitant elevated peripheral white blood cell
counts, CLL was diagnosed.
We determined the percentage of low-grade B-cell lym-
phoma in all femoral heads and in the group that was suit-
able according to the bone banking protocol. Patients
having low-grade B-cell lymphoma in the femoral head
were referred to a hematologist-oncologist for further
evaluation. Follow up of these patients consisted of clini-
cal and radiological assessment on a yearly basis, review
of hospital files and contact with family doctors. We
assessed patients who had symptoms of systemic disease
and who were treated by other physicians.
Results
From November 1994 to December 2005 we obtained
852 femoral heads removed at the time of primary total
hip replacement from 737 patients (205 men, 532
women), mean age 69 years (Range 23 to 94 years). We
reported earlier on the first 137 of these femoral heads
[15]. Fourteen of 852 femoral heads were highly suspi-
cious of low-grade B-cell lymphoma (1.6%). These four-
teen femoral heads were retrieved from 13 donors. Mean
age of these donors was 67 years (Range 51–79 years). Of
852 femoral heads, 504 fulfilled all criteria for donation
according to the existing guidelines of EAMST and AATB.
A total of 348 femoral heads were discarded because of a
positive donor history (questionnaire), an increased ESR,
or positive serological, histological or bacterial tests. They
were also discarded if malignant disease was diagnosed
within six months of donation. Some femoral heads have
been rejected because of incomplete information from the
screening tests. Six of 504 allografts fulfilling all criteria
for donation were excluded based solely on the his-
topathological features of B-cell lymphoma (1.2%). These
six femoral heads, retrieved from six different donors,Page 2 of 5
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found variable numbers of low-grade B-cell lymphoma
throughout the years. The distribution of low-grade B-cell
lymphoma for each year is shown in figure 1. We per-
formed long term follow up at a median of 7.2 years
(Range 1–12 years). In this long term follow up one
patient had developed a B-cell lymphoma in a lymph ves-
sel in the inguinal region on the contralateral side, three
years after the histopathological diagnosis of low-grade B-
cell lymphoma was established. She underwent a lymph
node excision and started with chemotherapy and radio-
therapy. Currently this patient has been stable (non-pro-
gressive disease) for three years but continues to be
monitored by a hematologist-oncologist. Another patient
developed chronic lymphatic leukemia. No treatment was
indicated but she is under the supervision of a hematolo-
gist-oncologist. Three other patients are still being moni-
tored on a yearly base by a hematologist. They have yet to
develop malignant disease.
Discussion
In routine histopathological screening of 852 femoral
heads, throughout the years we have found fourteen low-
grade B-cell Non-Hodgkin Lymphoma (NHL) in thirteen
patients. Even in the group of 504 femoral heads that were
eligible for bone transplantation, six femoral heads in six
patients were suspicious of low-grade B-cell lymphoma.
We have performed a long term follow up of these thir-
teen patients in which we diagnosed low-grade B-cell NHL
in their removed femoral heads. Two patients developed
systemic malignant disease; one of them needed medical
treatment for her condition. Three other patients are eval-
uated on a yearly basis by a hematologist.
Non-Hodgkin lymphoma (NHL) is a malignancy of the
lymphatic system, caused by uncontrolled proliferation of
B- or T-cell lymphocytes. It is relatively uncommon, but
the standardized incidence has increased dramatically in
the past few decades and is expected to increase by an
additional 36.1% between 2000 and 2020 [17,18]. Exten-
sive research to assess this increase shows a diversity of
potential risk factors, such as diet, environmental and
occupational factors, hair dye, viruses, hepatitis C infec-
tion, immunosuppression and blood transfusion. How-
ever, explanations accounting for all increases are not yet
available [19-27]. Treatment of patients with NHL
depends on histological type, clinical stage and prognostic
group [28]. In low-grade B-cell lymphoma, by the time of
diagnosis the disease is widespread and therefore incura-
ble, but only a small group of these patients develops sys-
temic malignant disease. Therefore a watch and wait
approach is indicated. Palliative chemotherapy can be
started at the time the patient presents with systemic man-
ifestation of disease [29]. In our study one of the thirteen
patients diagnosed with low-grade B-cell lymphoma
developed systemic malignant disease for which she
needed medical treatment. Four other patients are being
monitored on a yearly basis by a hematologist.
Recent literature questions the necessity of routine his-
topathological examination of retrieved femoral heads.
There are studies that find the cost-performance ratio of
routine histopathological evaluation unfavorable because
of the little clinical significance in changes of treatment
from the diagnoses found [30-34]. Other studies recom-
mend routine evaluation because of a recognized inci-
dence of unsuspected, malignant diagnoses and as a tool
for quality control [15,16,35]. The significance of these
diagnoses is still unknown, but patients with neoplastic
histopathological findings need monitoring and follow
up. To our best knowledge, transmission of low grade B-
cell lymphoma by bone donation has never been reported
in medical literature. On the other hand, it has never been
proven that bone with a (low grade) hematologous neo-
plasm is not transmissible by allogenic bone transplanta-
tion to an otherwise healthy recipient.
Distribution of low grade B cell lymphoma found in retrieved femoral heads throughout the years in routine histopathological screeningFigure 1
Distribution of low grade B cell lymphoma found in retrieved femoral heads throughout the years in routine 
histopathological screening.
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In conclusion, we found variable numbers of low-grade B-
cell lymphoma throughout the years in routine his-
topathological screening of femoral heads retrieved from
patients treated by total hip arthroplasty, even in a group
that was eligible for bone transplantation. Two patients
developed systemic malignant disease; one of them
needed medical treatment for her condition. Three other
patients are still evaluated on a yearly basis by a hematol-
ogist. Therefore, we recommend the routine histopatho-
logical evaluation of all femoral heads removed during
elective total hip arthroplasty as a tool for quality control,
whether the femoral head is used for bone banking or not.
In addition, all patients with neoplastic histopathological
findings need monitoring and follow up.
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